Monitoring Ponatinib in a Child with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Ponatinib is a third-generation tyrosine kinase inhibitor (TKI) reported to show a higher efficacy for adult Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) than other TKIs. However, few studies describe ponatinib for pediatric Ph+ALL; therefore, the efficacy, safety, and opti...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Case Rep Oncol
Glavni autori: Tanimura, Kazuki, Yamasaki, Kai, Okuhiro, Yuki, Hira, Kota, Nitani, Chika, Okada, Keiko, Fujisaki, Hiroyuki, Matsumoto, Kana, Hara, Junichi
Format: Artigo
Jezik:Inglês
Izdano: S. Karger AG 2021
Teme:
Case Report
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7983555/
https://ncbi.nlm.nih.gov/pubmed/33776678
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000511071
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items